A new class of antibiotics effective against methicillin-resistant
Staphylococcus aureus
(MRSA) is disclosed. Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penicillin-binding protein (PBP) 2a. This class of antibiotics holds promise in reversing obsolescence of staphylococcal PBPs as important targets for antibiotics. Embodiments of the invention thus provide novel antibacterial compounds that target penicillin-binding proteins and/or other important cellular targets. Methods for inhibiting the growth and/or replication of bacteria using the compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, including drug-resistant strains of
Staphylococcus aureus.
披露了一种新型抗生素,对
甲氧西林耐药
金黄色葡萄球菌(MRSA)有效。该类化合物可以通过结合
青霉素结合蛋白(PBP)2a的变构和催化结构域来破坏细胞壁
生物合成。这类抗生素有望扭转
金黄色葡萄球菌PBP作为抗生素重要靶点的过时现象。因此,本发明实施例提供了针对
青霉素结合蛋白和/或其他重要细胞靶点的新型抗菌化合物。还提供了使用所述化合物抑制细菌生长和/或复制的方法。各种实施例对革兰氏阳性菌表现出活性,包括耐药的
金黄色葡萄球菌菌株。